<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38237616</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study.</ArticleTitle><Pagination><StartPage>417</StartPage><EndPage>426</EndPage><MedlinePgn>417-426</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(23)00631-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(23)00631-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Novel oral polio vaccine type 2 (nOPV2) has been used to interrupt circulating vaccine-derived poliovirus type 2 outbreaks following its WHO emergency use listing. This study reports data on the safety and immunogenicity of nOPV2 over two rounds of a campaign in The Gambia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This observational cohort study collected baseline symptoms (vomiting, diarrhoea, irritability, reduced feeding, and reduced activity) and axillary temperature from children aged 6 weeks to 59 months in The Gambia before a series of two rounds of a nOPV2 campaign that took place on Nov 20-26, 2021, and March 19-22, 2022. Serum and stool samples were collected from a subset of the participants. The same symptoms were re-assessed during the week following each dose of nOPV2. Stool samples were collected on days 7 and 28, and serum was collected on day 28 following each dose. Adverse events, including adverse events of special interest, were documented for 28 days after each campaign round. Serum neutralising antibodies were measured by microneutralisation assay, and stool poliovirus excretion was measured by real-time RT-PCR.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Of the 5635 children eligible for the study, 5504 (97·7%) received at least one dose of nOPV2. There was no increase in axillary temperature or in any of the baseline symptoms following either rounds of the campaigns. There were no adverse events of special interest and no other safety signals of concern. Poliovirus type 2 seroconversion rates were 70% (95% CI 62 to 78; 87 of 124 children) following one dose of nOPV2 and 91% (85 to 95; 113 of 124 children) following two doses. Poliovirus excretion on day 7 was lower after the second round (162 of 459 samples; 35·3%, 95% CI 31·1 to 39·8) than after the first round (292 of 658 samples; 44·4%, 40·6 to 48·2) of the campaign (difference -9·1%; 95% CI -14·8 to -3·3), showing the induction of mucosal immunity.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">In a campaign in west Africa, nOPV2 was well tolerated and safe. High rates of seroconversion and evidence of mucosal immunity support the licensure and WHO prequalification of this vaccine.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Bill &amp; Melinda Gates Foundation.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bashorun</LastName><ForeName>Adedapo O</ForeName><Initials>AO</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotei</LastName><ForeName>Larry</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jawla</LastName><ForeName>Ousubie</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jallow</LastName><ForeName>Abdoulie F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saidy</LastName><ForeName>Aisha J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinteh</LastName><ForeName>Ma-Ansu</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kujabi</LastName><ForeName>Arafang</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jobarteh</LastName><ForeName>Tijan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanu</LastName><ForeName>Francis John</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donkor</LastName><ForeName>Simon A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezeani</LastName><ForeName>Esu</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fofana</LastName><ForeName>Sidat</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Expanded Programme on Immunization, Ministry of Health, Government of The Gambia, Kotu, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Njie</LastName><ForeName>Mbye</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Expanded Programme on Immunization, Ministry of Health, Government of The Gambia, Kotu, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceesay</LastName><ForeName>Lamin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Expanded Programme on Immunization, Ministry of Health, Government of The Gambia, Kotu, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafri</LastName><ForeName>Basit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeffries</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotanmi</LastName><ForeName>Brezesky</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainou</LastName><ForeName>Bernardo A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ooko</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Ed</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene &amp; Tropical Medicine, Banjul, The Gambia. Electronic address: ed.clarke@lshtm.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005714" MajorTopicYN="N" Type="Geographic">Gambia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>19</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>18</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38237616</ArticleId><ArticleId IdType="pmc">PMC10954559</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00631-X</ArticleId><ArticleId IdType="pii">S1473-3099(23)00631-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Global wild poliovirus 2016–2022. World Health Organization, Aug 30, 2022. https://polioeradication.org/wp-content/uploads/2022/09/weekly-polio-analyses-WPV-20220830.pdf</Citation></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8:e1002599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Global polio eradication initiative: strategy for the response to type 2 circulating vaccine-derived poliovirus 2020–2021. An addendum to the polio endgame strategy 2019. World Health Organization, 2023. http://polioeradication.org/wp-content/uploads/2020/04/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf</Citation></Reference><Reference><Citation>Voorman A, Lyons H, Bennette C, et al. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2023;41(suppl 1):A85–A92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10973941</ArticleId><ArticleId IdType="pubmed">35339308</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative Global circulating vaccine-derived polioviruses. 2021. https://polioeradication.org/polio-today/</Citation></Reference><Reference><Citation>Macklin GR, O'Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401–405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736–751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I, Leroux-Roels I, Bandyopadhyay AS, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397:39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397:27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148–158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, Mercer LD, De Leon T, et al. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials. Lancet Microbe. 2022;3:e912–e921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9712124</ArticleId><ArticleId IdType="pubmed">36332645</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO First ever vaccine listed under WHO emergency use. World Health Organization, Nov 13, 2020. https://www.who.int/news/item/13-11-2020-first-ever-vaccine-listed-under-who-emergency-use</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145–176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington C, Sun H, Jeffries-Miles S, et al. Culture-independent detection of poliovirus in stool samples by direct RNA extraction. Microbiol Spectr. 2021;9:e0066821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579935</ArticleId><ArticleId IdType="pubmed">34756088</ArticleId></ArticleIdList></Reference><Reference><Citation>Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Corrected version 2.1. July, 2017. https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf</Citation></Reference><Reference><Citation>Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–872.</Citation><ArticleIdList><ArticleId IdType="pubmed">9595616</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873–890.</Citation><ArticleIdList><ArticleId IdType="pubmed">9595617</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerland MW, Lydersen S, Laake P. Recommended tests and confidence intervals for paired binomial proportions. Stat Med. 2014;33:2850–2875.</Citation><ArticleIdList><ArticleId IdType="pubmed">24648355</ArticleId></ArticleIdList></Reference><Reference><Citation>Efron B. Better bootstrap confidence intervals. J Am Stat Assoc. 1987;82:171–185.</Citation></Reference><Reference><Citation>Pan African Clinical Trials Registry PACTR202010705577776: a phase 3, double-blind, randomized, controlled trial to assess the safety of a novel type 2 oral polio vaccine (nOPV2) in infants and young children and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13419</Citation></Reference><Reference><Citation>Climate Change Knowledge Portal The Gambia. World Bank Group, 2022. https://climateknowledgeportal.worldbank.org/country/gambia</Citation></Reference><Reference><Citation>Brewster DR, Greenwood BM. Seasonal variation of paediatric diseases in The Gambia, west Africa. Ann Trop Paediatr. 1993;13:133–146.</Citation><ArticleIdList><ArticleId IdType="pubmed">7687109</ArticleId></ArticleIdList></Reference><Reference><Citation>Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis. 2001;33:531–541.</Citation><ArticleIdList><ArticleId IdType="pubmed">11462191</ArticleId></ArticleIdList></Reference><Reference><Citation>de Deus N, Capitine IPU, Bauhofer AFL, et al. Immunogenicity of reduced-dose monovalent type 2 oral poliovirus vaccine in Mocuba, Mozambique. J Infect Dis. 2022;226:292–298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400415</ArticleId><ArticleId IdType="pubmed">33180924</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Gast C, Brickley EB, et al. A randomized phase 4 study of immunogenicity and safety after monovalent oral type 2 sabin poliovirus vaccine challenge in children vaccinated with inactivated poliovirus vaccine in Lithuania. J Infect Dis. 2021;223:119–127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781454</ArticleId><ArticleId IdType="pubmed">32621741</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzoev A, Macklin GR, Zhang Y, et al. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. Lancet Glob Health. 2022;10:e1807–e1814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9681660</ArticleId><ArticleId IdType="pubmed">36400086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy SB, Macklin GR, Mason Ross G, et al. Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey. Lancet Glob Health. 2023;11:e917–e923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10187988</ArticleId><ArticleId IdType="pubmed">37202026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper LV, Erbeto TB, Danzomo AA, et al. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study. Lancet Infect Dis. 2024 doi: 10.1016/S1473-3099(23)00688-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00688-6</ArticleId><ArticleId IdType="pubmed">38246190</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, Badizadegan K. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Front Public Health. 2023;11:1098419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080024</ArticleId><ArticleId IdType="pubmed">37033033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashkenazi A, Melnick JL. Heterotypic antibody response after feeding of monovalent attenuated live poliovaccine. N Engl J Med. 1962;267:1228–1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">13965178</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC, Praharaj I, Babji S, et al. The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial in seronegative Indian infants. Lancet Infect Dis. 2016;16:905–914.</Citation><ArticleIdList><ArticleId IdType="pubmed">27156189</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative GPEI statement on cVDPV2 detections in Burundi and Democratic Republic of the Congo. March 16, 2023. https://polioeradication.org/news-post/gpei-statement-on-cvdpv2-detections-in-burundi-and-democratic-republic-of-the-congo/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>